MedPath

Lumiliximab

Generic Name
Lumiliximab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
357613-86-6
Unique Ingredient Identifier
8Z13S29R5A
Background

Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints.

Indication

Investigated for use/treatment in asthma and leukemia (lymphoid).

Associated Conditions
-
Associated Therapies
-
© Copyright 2025. All Rights Reserved by MedPath